U071 Advancing HS Diagnosis with Artificial Intelligence: A Multi-Phased Collaborative Approach
DESCRIPTION
This session will present how innovative AI modeling can identify a distinct hidradenitis suppurativa (HS) phenotype comprising data elements from patients' health histories. This phenotype can distinguish HS patients who may otherwise remain undiagnosed from the broader population, providing clinical insight and the potential for reduced time to diagnosis and treatment. Such innovations can be applied to help recognize other diseases, allowing earlier access to treatment, and ultimately decrease patient suffering.
LEARNING OBJECTIVES
Demonstrate how a heterogeneous open claims data source, augmented with EHR data from the AAD’s DataDerm Clinical Data Registry, can be used to identify patients with hidradenitis suppurativa (HS).
Examine how AI can be used to isolate disease profiles to identify patients for early intervention and targeted treatment.
Compare the predictors of HS diagnosis identified by AI with the existing literature and our current understanding of the disease
SCHEDULE
8:00 AM
Intro to the Project, Overview of Patient Finder and Results
Steven Daniel Daveluy, MD, FAAD
8:10 AM
From Data to Diagnosis: What Dermatologists Should Know
Julia Mhlaba Riley, MD, FAAD
8:25 AM
Leveraging AI for Comprehensive HS Education Initiatives
Caryn Etkin, PhD, MPH
8:40 AM
Translating Data into Measurable Outcomes to Improve HS Patient Care: A QI Initiative
Martina J. Porter, MD, FAAD
8:55 AM
Q&A
DIRECTOR
Steven Daniel Daveluy, MD, FAAD
Wayne State University
SPEAKERS
Caryn Etkin, PhD, MPH
Martina J. Porter, MD, FAAD
Beth Israel Deaconess Medical Center & Harvard Medical School
Julia Mhlaba Riley, MD, FAAD
Northwestern Feinberg School of Medicine
HANDOUTS
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Caryn Etkin, PhD, MPH
No financial relationships exist with ineligible companies.
Martina J. Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding), Other(Residency/Fellowship Program Funding); Almirall – Consultant (1099 relationship)(Fees); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Avalo Therapeutics Inc – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Citryll – Advisory Board(Fees); Corvus Pharmaceuticals – Consultant (1099 relationship)(Fees); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Merck – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Investigator(Grants/Research Funding); Propeller Bio – Consultant (1099 relationship)(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Spyre Therapeutics – Consultant (1099 relationship)(Fees); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Ventyx Biosciences – Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Julia Mhlaba Riley, MD, FAAD
AbbVie – Investigator(Fees); Incyte Corporation – Investigator(Fees); MoonLake Immunotherapeutics – Investigator(Fees); Novartis – Investigator(Fees); UCB – Advisory Board(Fees);